Suprith Badarinath

A phase 2 safety study of accelerated elotuzumab infusion, over less than 1 h, in combination with lenalidomide and dexamethasone, in patients with multiple myeloma.

Authors:

James Berenson Robert Manges Suprith Badarinath Alan Cartmell Kristi McIntyre Roger Lyons Wael Harb Hesham Mohamed Ali Nourbakhsh Robert Rifkin

Am J Hematol 2017 May 22;92(5):460-466. Epub 2017 Mar 22.

US Oncology Research and Rocky Mountain Cancer Centers, Denver, Colorado.

View Article and Find Full Text PDF

May 2017

Phase II multicenter study of docetaxel and bevacizumab with or without trastuzumab as first-line treatment for patients with metastatic breast cancer.

Authors:

Lee S Schwartzberg Suprith Badarinath Mark R Keaton Barrett H Childs

Clin Breast Cancer 2014 Jun 27;14(3):161-8. Epub 2013 Dec 27.

Oncology, Sanofi US, LLC, Bridgewater, NJ.

View Article and Find Full Text PDF

June 2014

Phase II study of lapatinib in combination with vinorelbine, as first or second-line therapy in women with HER2 overexpressing metastatic breast cancer.

Authors:

Helen Kent Chew Lee Schwartzberg Suprith Badarinath Peter Rubin Grace Shumaker James Daugherty Michelle DeSilvio Janine Mahoney

Springerplus 2014 22;3:108. Epub 2014 Feb 22.

GlaxoSmithKline, Collegeville, PA USA.

View Article and Find Full Text PDF

June 2015

Addition of bevacizumab to three docetaxel regimens as adjuvant therapy for early stage breast cancer.

Authors:

Denise A Yardley Lowell Hart David Waterhouse Robert Whorf D Randolph Drosick Patrick Murphy Suprith Badarinath Brooke R Daniel Barrett H Childs Howard Burris

Breast Cancer Res Treat 2013 Dec 21;142(3):655-65. Epub 2013 Nov 21.

Sarah Cannon Research Institute, Tennessee Oncology, PLLC, 250 25th Avenue North, Suite 100, Nashville, TN, 37203, USA,

View Article and Find Full Text PDF

December 2013

Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer.

Clin Colorectal Cancer 2012 Jun 4;11(2):101-11. Epub 2011 Nov 4.

Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA.

View Article and Find Full Text PDF

June 2012

A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer.

Authors:

Ralph V Boccia Thomas M Cosgriff David L Headley Suprith Badarinath Shaker R Dakhil

Clin Colorectal Cancer 2010 Apr;9(2):102-7

Center for Cancer and Blood Disorders, Bethesda, MD 20817, USA.

View Article and Find Full Text PDF

April 2010

Publications by authors named "Suprith Badarinath"

A phase 2 safety study of accelerated elotuzumab infusion, over less than 1 h, in combination with lenalidomide and dexamethasone, in patients with multiple myeloma.

Authors:

Phase II multicenter study of docetaxel and bevacizumab with or without trastuzumab as first-line treatment for patients with metastatic breast cancer.

Authors:

Phase II study of lapatinib in combination with vinorelbine, as first or second-line therapy in women with HER2 overexpressing metastatic breast cancer.

Authors:

Addition of bevacizumab to three docetaxel regimens as adjuvant therapy for early stage breast cancer.

Authors:

Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer.

Authors:

A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer.

Authors: